ArticleCureus2025
Effects of Thyroid Hormone Replacement Therapy on Lipid Profiles in Patients With Hypothyroidism.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypothyroidism is associated with dyslipidemia and increased cardiovascular risk. Thyroid hormone replacement therapy (THRT) restores thyroid function and may improve lipid metabolism. This study evaluated the effects of THRT on lipid profiles in hypothyroid patients and identified predictors of cardiovascular risk reduction.
methodsA retrospective analysis was conducted on 350 patients with hypothyroidism (183 females, 52.3%; 167 males, 47.7%). The mean age was 48.6 ± 13.2 years (range 18-82). The mean BMI was 27.4 ± 4.9 kg/m², with 105 (30.0%) normal weight, 145 (41.4%) overweight, and 100 (28.6%) obese. At baseline, mean thyroid-stimulating hormone (TSH) was 16.3 ± 7.4 mIU/L and free thyroxine (FT4) was 0.84 ± 0.32 ng/dL. Lipid levels showed dyslipidemia: total cholesterol (TC): 238.5 ± 42.3 mg/dL, low-density lipoprotein cholesterol (LDL-C): 142.8 ± 31.5 mg/dL, high-density lipoprotein cholesterol (HDL-C): 44.7 ± 9.5 mg/dL, and triglycerides (TG): 176.4 ± 56.2 mg/dL.
resultsAfter an average treatment duration of 18.4 ± 8.7 months, significant reductions were observed in TC (201.3 ± 36.5 mg/dL; -37.2 mg/dL, p < 0.001), LDL-C (118.6 ± 27.2 mg/dL; -24.2 mg/dL, p < 0.001), and TG (156.1 ± 51.3 mg/dL; -20.3 mg/dL, p < 0.001). HDL-C improved modestly (47.9 ± 10.4 mg/dL; +3.2 mg/dL, p < 0.001). Greater benefits were seen in patients with high baseline TSH and LDL-C. Patients with diabetes (n = 102, 29.1%), hypertension (n = 84, 24.0%), or both (n = 67, 19.1%) had lower rates of lipid improvement compared with those without comorbidities (n = 97, 27.7%). Machine learning models demonstrated modest accuracy (receiver operating characteristic curve-area under the curve (ROC-AUC): 0.51-0.56) but confirmed baseline lipids, thyroid hormones, comorbidities, and medication type as key predictors.
conclusionTHRT significantly improved lipid profiles and reduced cardiovascular risk in hypothyroid patients, supporting its role as a cornerstone of comprehensive management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.